Feb 4, 2022

Dublin, IRELAND Dublin, Feb. 04, 2022 (GLOBE NEWSWIRE) -- The "Global CRISPR Market 2021-2028" report has been added to ResearchAndMarkets.com's offering. The global CRISPR market is anticipated to display growth at a CAGR of 20.38% through the projected period of 2021-2028. Factors such as growing lifestyle-oriented diseases and the surging prevalence of genetic diseases are widening the scope of the CRISPR market globally. Additionally, the advancements in gene-based therapy in the agriculture sector, coupled with the increased need for clinical trials, are opening new avenues for the global market over the forecasted period. In contrast, the rising ethical concerns relating to technology use and the absence of healthcare budgets in developing nations hamper the overall development of the CRISPR market. Regional Outlook The Asia-Pacific is estimated to observe the fastest growth in the CRISPR market over the considered phase. This growth can be attributed to the continuous research and development activities across India and China. Moreover, these countries have well-developed agriculture research facilities to develop effective and productive crops. Furthermore, the growing reliance on non-vegetarian foods, such as red meat and seafood, contributes to the market's development over the projected phase. Above all, the rising demand for aquaculture predominantly drives the growth of the CRISPR market across the APAC region. Competitive Outlook The prominent companies in the CRISPR market are Integrated DNA Technologies, Intellia therapeutics, Horizon Discovery Group, Precision Biosciences, Genscript, Novartis International AG, Editas Medicine, Caribou Biosciences Inc, Synthego Corporation, OriGene Technologies Inc, Cellectis Bioresearch SAS, CRISPR therapeutics AG, Addgene, New England Biolabs, and Lonza Group Ltd. Key Topics Covered